|
End-of-day quote
Shanghai S.E.
2026-10-30
|
5-day change | 1st Jan Change | ||
| 6.500 CNY | -0.46% |
|
-2.99% | -1.22% |
| Market Cap | 3.5B 526M 471M 433M 392M 734M 49.92B 747M 5.17B 2.07B 26.26B 1.97B 1.93B 82.82B | P/E 2024 |
56.1x | P/E 2025 | 60.6x |
|---|---|---|---|---|---|
| Enterprise Value | 3.95B 593M 531M 488M 443M 827M 56.3B 843M 5.83B 2.34B 29.62B 2.23B 2.18B 93.4B | EV / Sales 2024 |
1.85x | EV / Sales 2025 | 2.32x |
| Free-Float |
67.44% | Yield 2024 |
0.55% | Yield 2025 | 0.21% |
| 1 day | -0.46% | ||
| 1 week | -2.99% | ||
| Current month | -17.62% | ||
| 1 month | -17.41% | ||
| 3 months | -5.66% | ||
| 6 months | -7.54% | ||
| Current year | -1.22% |
| 1 week | 6.38 |  | 6.79 |
| 1 month | 6.3 | | 8.05 |
| Current year | 6.3 | | 9.05 |
| 1 year | 6.25 | | 9.44 |
| 3 years | 3.75 | | 9.44 |
| 5 years | 3.75 | | 10.17 |
| 10 years | 3.05 | | 10.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jing Liang Li
CEO | Chief Executive Officer | 57 | 2023-06-24 |
Hai Lin Zhao
DFI | Director of Finance/CFO | 51 | 2011-11-14 |
Ting Wu
IRC | Investor Relations Contact | 37 | 2022-02-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Jing Liang Li
CHM | Chairman | 57 | 2013-08-20 |
Jian Chao Luo
BRD | Director/Board Member | 53 | 2023-06-24 |
Liang Fang
BRD | Director/Board Member | 63 | 2021-08-10 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.46% | -2.99% | +1.09% | +6.91% | 528M | |
| +3.19% | +8.48% | +74.25% | +153.03% | 1,224B | |
| -0.73% | +2.09% | +46.41% | +87.64% | 662B | |
| +1.41% | +3.40% | +30.98% | +112.26% | 514B | |
| +0.42% | +2.88% | +54.92% | +69.67% | 388B | |
| +2.18% | +1.55% | +72.70% | +45.42% | 361B | |
| +1.12% | +3.80% | +35.82% | +59.72% | 302B | |
| +6.96% | +7.55% | +11.15% | +37.89% | 271B | |
| +1.15% | +4.19% | +59.72% | +78.16% | 249B | |
| +3.06% | +8.58% | +44.03% | +122.76% | 205B | |
| Average | +1.88% | +2.23% | +43.11% | +77.35% | 417.74B | |
| Weighted average by Cap. | +2.04% | +3.04% | +53.35% | +100.41% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 1.94B 292M 261M 240M 218M 407M 27.7B 415M 2.87B 1.15B 14.57B 1.09B 1.07B 45.95B | 1.76B 264M 237M 218M 197M 368M 25.08B 375M 2.59B 1.04B 13.19B 991M 970M 41.6B |
| Net income | 50.53M 7.59M 6.8M 6.25M 5.67M 10.59M 721M 10.79M 74.58M 29.94M 379M 28.49M 27.88M 1.2B | 60M 9.01M 8.07M 7.43M 6.73M 12.58M 856M 12.81M 88.56M 35.55M 450M 33.83M 33.11M 1.42B |
| Net Debt | 765M 115M 103M 94.66M 85.77M 160M 10.91B 163M 1.13B 453M 5.74B 431M 422M 18.1B | 447M 67.16M 60.15M 55.32M 50.13M 93.7M 6.38B 95.46M 660M 265M 3.35B 252M 247M 10.58B |
Employees
2,084
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-29 | CN¥6.500 | -0.46% | 13,704,630 |
| 26-10-29 | CN¥6.530 | -0.61% | 9,499,100 |
| 26-10-28 | CN¥6.570 | +2.66% | 8,460,600 |
| 26-10-27 | CN¥6.400 | -2.59% | 9,496,300 |
| 26-10-26 | CN¥6.570 | -1.20% | 6,893,199 |
- Stock Market
- Stocks
- 600222 Stock
Select your edition
All financial news and data tailored to specific country editions
